Nanotherapy: Treating deadly brain tumors by delivering big radiation with tiny tools

March 20, 2012, University of Texas Health Science Center at San Antonio

For the past 40 years, radiation has been the most effective method for treating deadly brain tumors called glioblastomas. But, although the targeting technology has been refined, beams of radiation still must pass through healthy brain tissue to reach the tumor, and patients can only tolerate small amounts before developing serious side effects.

A group of researchers at The University of Texas Health Science Center at San Antonio have developed a way to deliver nanoparticle radiation directly to the and keep it there. The method doses the tumor itself with much higher levels of radiation — 20 to 30 times the current dose of radiation therapy to patients — but spares a much greater area of .

The study, published today in the journal Neuro-Oncology, has been successful enough in laboratory experiments that they're preparing to start a clinical trial at the Cancer Therapy & Research Center, said Andrew Brenner, M.D., Ph.D., the study's corresponding author and a neuro-oncologist at the CTRC who will lead the clinical trial.

"We saw that we could deliver much higher doses of radiation in animal models," Dr. Brenner said. "We were able to give it safely and we were able to completely eradicate tumors."

The radiation comes in the form of an isotope called rhenium-186, which has a short half-life. Once placed inside the tumor, the rhenium emits that only extends out a few millimeters.

But simply putting the rhenium into a brain tumor would not work well without a way to keep it there — the tiny particles would be picked up by the bloodstream and carried away. That problem was solved by a team led by nuclear medicine physician William T. Phillips, M.D., and biochemist Beth A. Goins, Ph.D., in the Department of Radiology; and Ande Bao, Ph.D., a medical physicist and pharmaceutical chemist in the Department of Otolaryngology, all of the School of Medicine at the Health Science Center. They encapsulated the rhenium in miniscule fat molecules, or liposomes, about 100 nanometers across.

"The technology is unique," Dr. Brenner said. "Only we can load the liposomes to these very high radioactivity levels."

The doctors hope to launch the clinical trial by summer.

Explore further: Higher radiation dose does not help lung cancer patients live longer

Related Stories

Higher radiation dose does not help lung cancer patients live longer

October 3, 2011
A higher dose of radiation (74 Gy) does not improve overall survival for non-small cell lung cancer that has spread to the lymph nodes, compared to the standard radiation dose (60 Gy), according to an interim analysis of ...

Immunogene therapy combined with standard treatment is safe for patients with brain tumors

August 15, 2011
A clinical trial has shown that a form of gene therapy is safe for treating a deadly form of brain cancer, even when combined with radiation therapy.

Recommended for you

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Scientists block the siren call of two aggressive cancers

January 23, 2018
Aggressive cancers like glioblastoma and metastatic breast cancer have in common a siren call that beckons the bone marrow to send along whatever the tumors need to survive and thrive.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.